NextCure, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of novel immunomedicines to treat cancer and other diseases related to the immune system by restoring normal immune function. The company is headquartered in Beltsville, Maryland.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-54.20M |
| EBITDA | $-54.28M |
| Operating Margin | 0.00% |
| Return on Equity | -132.40% |
| Return on Assets | -66.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $7.41 |
| Price-to-Book | 0.25 |
| Price-to-Sales (TTM) | 9.52 |
| EV/Revenue | 117.33 |
| EV/EBITDA | 0.51 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $3.61M |
| Float | $2.26M |
| % Insiders | 14.80% |
| % Institutions | 62.40% |
Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.
BELTSVILLE, Md., June 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, today announced the replay availability for its virtual key opinion leader (KOL) event on SIM0505, held following the Company's ASCO 2026 poster presentation of first reported clinical efficacy data from its Phase 1 dose escalation study (June 1, 2026 press release).
55% ORR in gynecologic cancers with 52.9% in ovarian and 66.7% in USC at 12 weeks by best response per RECIST 1.1 within the therapeutic dose range (4.8 – 8.0 mg/kg) Favorable safety and tolerability in heavily pretreated population supports ongoing Phase 1 dose-optimization with emphasis on PROC NextCure to host virtual Key Opinion Leader (KOL) Event June 2, 2026 at 8 AM ET BELTSVILLE, Md., June 01, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, and Simcere Zaiming Pharmaceutical Co., Ltd.
BELTSVILLE, Md., May 07, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, today provided a business update and reported first quarter 2026 financial results.
BELTSVILLE, Md., May 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere) an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), today announced initiation of the dose optimization portion of the Phase 1 study of SIM0505, focusing on patients with platinum-resistant ovarian cancer. SIM0505 is an investigational antibody drug conjugate (ADC) comprised of an antibody that targets Cadherin-6 (CDH6) and a proprietary topoisomerase 1 inhibitor (TOPOi) payload.
Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026 Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026
BELTSVILLE, Md., April 07, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced that the U.S. Food And Drug Administration (FDA) has granted Fast Track Designation for SIM0505 for the treatment of platinum-resistant ovarian cancer. SIM0505 is an investigational antibody drug conjugate (ADC) comprised of an antibody that targets Cadherin-6 (CDH6) and a proprietary topoisomerase 1 inhibitor (TOPOi) payload.
